Recent clinical and preclinical studies highlight key therapeutic advances across oncology and neurology. Amgen’s cholesterol-lowering drug Repatha demonstrated cardiovascular event reduction in a 12,000-patient trial, potentially expanding its market. BioAtla and Cellectar Biosciences presented early-stage data on antibody-drug conjugates and alpha therapy targeting solid tumors and pancreatic cancer, respectively. Additionally, Medtronic’s adaptive deep brain stimulation system proved effective and safe for Parkinson’s disease patients in a long-term home study, advancing neuromodulation approaches.